Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Axovant Sciences Ltd. (AXON): Billionaire Andreas Halvorsen’s Viking Global Acquires Dispositive Power Over 75 Million Shares

According to a new 13D filing with the SEC, billionaire Andreas Halvorsen‘s Viking Global may be deemed to have “dispositive power” over 75 million shares of Axovant Sciences Ltd. (NYSE:AXON), which amass 75.6% of the company’s outstanding stock. This is due to Dr. Andrew Lo’s appointment to the Board of Directors of Axovant Sciences, upon which Viking Global gained the right to override certain decisions made by the company, including dispositions of common shares, though only with the support of two other major shareholders of Axovant Sciences. Viking Global doesn’t currently beneficially own any shares or securities of Axovant Sciences (NYSE:AXON).

Axovant Sciences, previously known as Roivant Neurosciences, is a biopharmaceutical company engaged in producing therapeutics to help treat people who suffer from dementia. Over the past 12 months, the company’s stock is down by 30.35%. Recently, Leering Swann and HC Wainwright reiterated their ‘Buy’ ratings on Axovant Sciences’ stock. For the company’s fiscal year 2016 ended March 31, the company reported a net loss of $133.1 million and a loss per share of $1.41.

There were 11 smart money investors in our database long Axovant Sciences (NYSE:AXON) at the end of March, out of which Peter Kolchinsky’s RA Capital Management held the most valuable position, worth around $57.4 million. The second-biggest stake was reported by Jacob Gottlieb’s Visium Asset Management, valued at $48.1 million. Some other hedge funds with similar bullishness included D E Shaw, founded by David E. Shaw, and Joseph Edelman’s Perceptive Advisors.

Andreas Halvorsen

Among the new investors of Axovant Sciences (NYSE:AXON) during the first quarter were Anders Hove and Bong Koh’s VHCP Management, which initiated the largest position, worth $2.1 million. Hal Mintz’s Sabby Capital, Mike Vranos’ Ellington, and Jeremy Green’s Redmile Group also added the stock to their portfolios during the quarter.

You can access the original SEC filing by clicking here.

Follow Axovant Sciences Ltd.
Trade (AXON) Now!

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Viking Global Investors 0 0 0 75,000,000 75,000,000 75.6%
Viking Global Performance 0 0 0 75,000,000 75,000,000 75.6%
Viking Global Equities 0 0 0 75,000,000 75,000,000 75.6%
Viking Global Equities II 0 0 0 75,000,000 75,000,000 75.6%
VGE III Portfolio Ltd 0 0 0 75,000,000 75,000,000 75.6%
Viking Long Fund GP 0 0 0 75,000,000 75,000,000 75.6%
Viking Long Fund Master Ltd 0 0 0 75,000,000 75,000,000 75.6%
Viking Global Opportunities GP 0 0 0 75,000,000 75,000,000 75.6%
Viking Global Opportunities Portfolio GP 0 0 0 75,000,000 75,000,000 75.6%
Viking Global Opportunities Illiquid Investments Sub-Master 0 0 0 75,000,000 75,000,000 75.6%
O. Andreas Halvorsen 0 0 0 75,000,000 75,000,000 75.6%
David C. Ott 0 0 0 75,000,000 75,000,000 75.6%
Daniel S. Sundheim 0 0 0 75,000,000 75,000,000 75.6%

Andreas Halvorsen
Andreas Halvorsen
Viking Global

Page 1 of 21 – SEC Filing


(Rule 13d-101)


Axovant Sciences Ltd.
(Name of Issuer)
Common Shares, $0.00001 par value
(Title of Class of Securities)
(CUSIP Number)

Eric Komitee

General Counsel

55 Railroad Avenue

Greenwich, Connecticut 06830


Address and Telephone Number of Person

to Receive Notices and Communications)

July 8, 2016
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ¨

Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7
for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 21 Pages)


* The remainder of this cover page shall be filled
out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Follow Axovant Sciences Ltd.
Trade (AXON) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.